Company profile: SpliceBio
1.1 - Company Overview
Company description
- Provider of genetic medicines using a proprietary Protein Splicing platform to develop gene therapies for genetic diseases, enabling delivery of large genes that cannot be packaged into single AAV vectors. Programs include a Stargardt disease therapy targeting ABCA4 and gene therapy initiatives in other therapeutic areas.
Products and services
- Gene Therapy Programs for Other Therapeutic Areas: Platform-enabled initiatives that develop genetic medicines for diverse diseases beyond ophthalmology, leveraging Protein Splicing to craft novel treatment options across multiple indications
- Protein Splicing Platform: Proprietary system that engineers gene therapies by enabling delivery of large genes that cannot be packaged into single AAV vectors, targeting diseases driven by large-gene mutations
- Stargardt Disease Gene Therapy: Gene-specific program that develops a therapy targeting Stargardt disease—an inherited retinal disorder caused by ABCA4 mutations—using company technologies to create novel treatment options
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to SpliceBio
Floragenex
HQ: United States
Website
- Description: Provider of innovative genomic analysis solutions for human, plant, and animal systems. Oregon-based privately owned biotechnology company delivering results in hundreds of genomics studies since 2007, supporting research in genetics, ecology, evolutionary biology, and biomedical fields.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Floragenex company profile →
GeneInsight
HQ: United States
Website
- Description: Provider of an IT platform that streamlines data interpretation and management; GeneInsight Suite has been in clinical use and evolving since 2005, developed at Partners HealthCare in collaboration with leading geneticists, laboratory operations personnel, practicing physicians, and IT professionals.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full GeneInsight company profile →
Nightstar Therapeutics
HQ: United Kingdom
Website
- Description: Provider of biopharmaceutical gene therapy research and development focused on retinal dystrophies, aiming to enable treatments for rare conditions caused by single-gene mutations; U.K. startup.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Nightstar Therapeutics company profile →
Precision BioSciences
HQ: United States
Website
- Description: Provider of ARCUS genome editing technology using sequence-specific nucleases to modify DNA in living cells and tissues, a Manufacturing Center for Advanced Therapeutics for production of advanced therapies, PBGENE-HBV targeting chronic hepatitis B, and partnerships for in vivo gene editing and ex vivo CAR T-cell therapy development.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Precision BioSciences company profile →
Quanterix
HQ: United States
Website
- Description: Provider of ultrasensitive biomarker detection solutions for healthcare, leveraging Simoa technology to enable earlier disease detection and improved treatment by measuring biomarkers at lower levels. Offerings include Simoa assays across neurology, oncology, cardiology, immunology and infectious disease; the HD-X automated immunoassay analyzer; SP-X and SR-X detection systems; and the CLIA-certified Simoa Accelerator Laboratory.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Quanterix company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for SpliceBio
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to SpliceBio
2.2 - Growth funds investing in similar companies to SpliceBio
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for SpliceBio
4.2 - Public trading comparable groups for SpliceBio
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →